🟢 Eupraxia Pharmaceuticals is trading 10.85% up in after-hours trading after durable symptom improvement in RESOLVE trial

Eupraxia Pharmaceuticals is trading now 10.85% up at $7.56 after new RESOLVE trial data showed durable symptom improvement in eosinophilic esophagitis.

• Moderate or severe painful swallowing declined from 62% at baseline to 25% after one year.
• Patients reporting no symptoms increased from 15% to 50%.
• The company-specific clinical update appears to be the clearest catalyst for the after-hours move; the treatment remains investigational, and the company has no current product revenue.